Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Feb:100:61-67.
doi: 10.1016/j.peptides.2017.12.009.

Newer GLP-1 receptor agonists and obesity-diabetes

Emily Brown  1 , Daniel J Cuthbertson  1 , John P Wilding  2
Affiliations
Review

Newer GLP-1 receptor agonists and obesity-diabetes

Emily Brown et al. Peptides. 2018 Feb.

Abstract

Obesity is a major risk factor for type 2 diabetes and may complicate type 1 diabetes. In parallel with the global epidemic of obesity, the incidence of type 2 diabetes is increasing exponentially. To reverse these alarming trends, weight loss becomes a major therapeutic priority in prevention and treatment of type 2 diabetes. Given that glucagon-like peptide-1 receptor agonists (GLP-1 RAs) improve glycaemic control and cause weight loss, they are receiving increasing attention for the treatment of diabetes-obesity. This review discusses current and emerging therapeutic options with GLP-1 RAs and considers the next generation of novel peptide co-agonists with the potential for improved therapeutic outcomes in obesity and type 2 diabetes.

Keywords: Diabetes; GLP-1 agonists; Obesity; Review.

PubMed Disclaimer

MeSH terms